Xconomy | Boston - Business + Technology in the Exponential Economy

Biogen and Icahn Duel Again, Marinus Gets $20M, Vigilance Urged on Patent Reform, & More Boston-Area Life Sciences News
A123Systems Counts to $69M, Sun Catalytix Out to Grow Seed From Polaris, Synageva Gets $30M, & More Boston-Area Deals News
U.S. Venture Funding Plummets (Yada Yada), But New England Less So—Region’s Top 10 Deals of Q1
Intellikine Attracts Novartis, Biogen, and Others for $51M Second Round
Calixa Passes Key Safety Test in Clinical Trial of New Antibiotic

Marinus Pharma Finds $20M in 2nd Round

Marinus Pharmaceuticals, a Branford, CT-based developer of drugs for neurological and psychiatric disorders, says it has closed a $20 million Series B round of financing from existing investors including Canaan Partners, Domain Associates, Foundation Medical Partners, and Sofinnova Ventures. The funding is intended to further develop the firm’s lead drug candidate, ganaxolone, as an additional treatment for refractory partial seizures and other conditions. Marinus says it has raised a total of $50 million in private financing.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.

Comments | Reprints | Share: